Kodiak Sciences to Present at Upcoming Investor Conferences

Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial biotechnology firm focused on retinal therapeutics, has announced that Dr. Victor Perlroth, the company’s CEO, will present at two upcoming investor conferences. The first is the Jefferies Global Healthcare Conference in London, scheduled for November 17, 2025, at 4:30 PM GMT (8:30 AM PST), where Dr. Perlroth will deliver a presentation. The second event is the 8th Annual Evercore Healthcare Conference in Coral Gables, Florida, on December 3, 2025, at 3:00 PM EST (12:00 PM PST), in which he will participate in a fireside chat. Live webcasts of both events will be accessible on Kodiak's website and will be available for replay for a limited time post-event.

Kodiak Sciences is dedicated to developing transformative therapies aimed at preventing and treating major causes of blindness globally. Its proprietary ABC® Platform embodies a novel approach to retinal drug development, integrating molecular engineering with both protein-based and chemistry-based therapy methodologies. The firm is progressing several late-stage clinical programs, notably including Tarcocimab and KSI-501, both of which are in two Phase 3 trials for retinal vascular diseases targeting the expansive $15 billion anti-VEGF market. Additionally, KSI-101, a bispecific protein, is under investigation in two Phase 3 studies for Macular Edema Secondary to Inflammation (MESI).

Through its innovative research and strategic initiatives, Kodiak Sciences is positioning itself as a key player in the retinal treatment landscape, with the potential to substantially impact patient care in ophthalmology. For more details, Kodiak encourages visits to their corporate website.

Kodiak Sciences Inc. (Nasdaq: KOD), a biotechnology firm focused on retinal diseases, is gearing up for key presentations at upcoming investor conferences, specifically the Jefferies Global Healthcare Conference and the Evercore Healthcare Conference. Both events present an opportunity for Kodiak to communicate its strategic vision, clinical progress, and commitment to developing transformative therapeutics in the retina space.

Investors should note that Kodiak's lead programs, Tarcocimab and KSI-501, are nearing critical Phase 3 studies aimed at addressing retinal vascular diseases within a lucrative $15 billion anti-VEGF market. Their innovative ABC® Platform, which integrates protein-based and chemistry-based therapies, positions Kodiak at the forefront of retinal medicine. Continuous investor engagement during these conferences could catalyze market interest, especially as the company prepares for potential commercialization.

The outcomes of these presentations can significantly impact stock performance. It is essential for investors to pay close attention to the company's announcements regarding clinical results, partnerships, regulatory submissions, and financial guidance during these events. A positive update could enhance investor confidence and drive share price appreciation as Kodiak capitalizes on its unique value proposition.

Investors should also consider the inherent volatility associated with biotechnology stocks, particularly those in late-stage clinical trials. Any negative news regarding trial results or regulatory hurdles may lead to sharp price declines. Therefore, while Kodiak presents a compelling investment opportunity based on its pipeline and market potential, it is advisable to maintain a cautious approach.

In summary, as Kodiak Sciences prepares for its upcoming presentations, investors should keep a close eye on market sentiments and company updates, as these could provide insight into both short-term and long-term investment prospects.